TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29721714

Group type: EXPERIMENTAL
Intervention: Early oral feeding after distal gastrectomy (DG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early oral feeding after total gastrectomy (TG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional postoperative management after distal gastrectomy (DG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional postoperative management after total gastrectomy (TG)
Number of subjects: 0
Study: 26768692

Group type: EXPERIMENTAL
Intervention: CF-on (CF >10 grams; n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CF-off (CF blinded; n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CF-off
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CF-on
Number of subjects: 50
Study: 24397625

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH)
Number of subjects: 58
Study: 22658249

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 μg/kg plus Ropivacaine 0.5mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 μg/kg, Ropivacaine 0.5mg/kg plus Epinephrine 6 μg/kg
Number of subjects: 40
Study: 20421121

Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 18697911

Group type: EXPERIMENTAL
Intervention: High protein diet (HP; 3.0 g protein x kg fat‐free mass (FFM)(‐1) x day(‐1))
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual protein intake (UP; 1.5 g protein x kg FFM(‐1) x day(‐1))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 19
Study: 15716250

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonaccelerated rehabilitation
Number of subjects: 25
Study: 12374436

Group type: EXPERIMENTAL
Intervention: Induction of emotional state (happiness, sadness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional states (happiness, sadness)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sentence unscrambling task (neutral, emotional sentences)
Number of subjects: 0
Study: 9931535

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for 3 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment for 3 days
Number of subjects: 28
Study: 7574816

Group type: COMPARATOR
Intervention: Granisetron monotherapy (40 micrograms/kg)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Granisetron plus steroids (500 mg of methylprednisolone succinate or 8 mg of dexamethasone phosphate prior to granisetron)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Granisetron plus steroids
Number of subjects: 122

Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 122
Study: 2407208

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 224831

Group type: EXPERIMENTAL
Intervention: Day treatment plus drugs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Drugs alone
Number of subjects: 10
Study: 31805462

Group type: EXPERIMENTAL
Intervention: Short story about two foresters solving a resource dilemma
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition: Short informative story on urban gardening
Number of subjects: 132
Study: 31056202

Group type: EXPERIMENTAL
Intervention: MEAL Plan
Number of subjects: 38

Group type: COMPARATOR
Intervention: Parent Education
Number of subjects: 38
Study: 27810522

Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Restarting quadruple therapy
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Reintroduction of ethambutol
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Addition of ciprofloxacin
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Average treatment duration
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Paradoxical reaction occurrence
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Median delay to onset of paradoxical reaction
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Predictive factors for paradoxical reaction
Number of subjects: 501
Study: 26290749

Group type: EXPERIMENTAL
Intervention: Patient education (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Education of patient associated with an active member of the family (n = 30)
Number of subjects: 60
Study: 23986910

Group type: EXPERIMENTAL
Intervention: 12-month home-based rehabilitation program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 81
Study: 20503074

Group type: EXPERIMENTAL
Intervention: CPAP with controlled heated breathing tube humidifier (cHH)
Number of subjects: 44
Study: 19448527

Group type: EXPERIMENTAL
Intervention: Late diagnosis of HIV infection in truck drivers
Number of subjects: 0
Study: 16459223

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg daily) and Vitamin C (750 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No vitamin supplementation (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (vitamin and non-vitamin)
Number of subjects: 30
Study: 15225192

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg/day (E + D group, n = 140)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 5 mg/day (E + P group, n = 139)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Both groups (E + D and E + P)
Number of subjects: 279
Study: 11679932

Group type: EXPERIMENTAL
Intervention: Praziquantel plus placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Artesunate plus placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Artesunate and praziquantel
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 10223131

Group type: EXPERIMENTAL
Intervention: Ribavirin group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 7838444

Group type: EXPERIMENTAL
Intervention: 123I-IBZM SPECT
Number of subjects: 22

Group type: COMPARATOR
Intervention: 11C-raclopride PET
Number of subjects: 22
Study: 3045435

Group type: EXPERIMENTAL
Intervention: Sinemet CR-4
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard Sinemet
Number of subjects: 23
Study: 31974825

Group type: EXPERIMENTAL
Intervention: Hypoxia (air-nitrogen-carbon dioxide mixture with decreased oxygen content) for 90 min
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 9
Study: 28941936

Group type: EXPERIMENTAL
Intervention: ProBalance rehabilitation programme (12 weeks, 90-min sessions, 2 days per week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control group (maintained usual activities)
Number of subjects: 52
Study: 26885407

Group type: EXPERIMENTAL
Intervention: Practice group (completed six 30-minute practice sessions of three lab-based inhibition tasks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Practice group
Number of subjects: 48
Study: 26205910

Group type: EXPERIMENTAL
Intervention: Intervention using supplements to increase the intake of EPA and DHA for 12 months
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intervention using supplements to increase the intake of EPA and DHA
Number of subjects: 204
Study: 23527521

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 88
Study: 21921571

Group type: EXPERIMENTAL
Intervention: GH 33 μg/kg/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GH 67 μg/kg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 124
Study: 17931758

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (radiochemotherapy)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Adjuvant treatment (surgery and postoperative radiation)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Adjuvant treatment
Number of subjects: 128
Study: 16376314

Group type: EXPERIMENTAL
Intervention: Modal triangle
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amodal triangle
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Figure with outlined inducers
Number of subjects: 26

Group type: COMPARATOR
Intervention: No-triangle figure
Number of subjects: 26
Study: 12364988

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum (PP) during laparoscopic GBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of PP and Reverse Trendelenburg (RT) during laparoscopic GBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sequential compression devices during PP and RT in laparoscopic GBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg (RT) during open GBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sequential compression devices during RT in open GBP
Number of subjects: 30
Study: 10666558

Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 11 mg of midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg of scopolamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8879892

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms twice daily
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 micrograms twice daily
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 micrograms twice daily
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100, 250, and 500 micrograms)
Number of subjects: 304
Study: 1947729

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 12
Study: 6344899

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Nuelin SA) 350 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Nuelin SA) 700 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled salbutamol alone
Number of subjects: 19
Study: 31243588

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (steroid)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide plus tenoxicam (steroid plus tenoxicam)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 29609103

Group type: EXPERIMENTAL
Intervention: Cognitive control training (two-week, six-session program)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 52
Study: 27461426

Group type: EXPERIMENTAL
Intervention: Asenapine (2.5-10 mg twice daily)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 24275900

Group type: EXPERIMENTAL
Intervention: Heated humidifiers (HH)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Heat and moisture exchangers (HME)
Number of subjects: 247
Study: 23050440

Group type: EXPERIMENTAL
Intervention: VA supplementation with 600 microg/d retinyl acetate
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: VA supplementation with 400 microg/d retinyl acetate
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: VA supplementation with 200 microg/d retinyl acetate
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with 0 microg/d retinyl acetate
Number of subjects: 115
Study: 20050759

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Infliximab (for Group III)
Number of subjects: 68
Study: 18227782

Group type: EXPERIMENTAL
Intervention: Family psychoeducational treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial control condition
Number of subjects: 0
Study: 16002035

Group type: EXPERIMENTAL
Intervention: Memantine (10, 20, or 30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11591884

Group type: EXPERIMENTAL
Intervention: Whey protein (W; 1.2 g/kg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Whey protein and creatine monohydrate (WC; 0.1 g/kg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (P; 1.2 g/kg/day maltodextrin)
Number of subjects: 36
Study: 9849446

Group type: EXPERIMENTAL
Intervention: 4‐HPR (fenretinide)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 28
Study: 8022293

Group type: EXPERIMENTAL
Intervention: Adapted form of the Peabody Picture Vocabulary Test-Revised
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard form of the Peabody Picture Vocabulary Test-Revised
Number of subjects: 25
Study: 2649319

Group type: EXPERIMENTAL
Intervention: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied twice a day
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied once a day
Number of subjects: 348
Study: 19531879

Group type: EXPERIMENTAL
Intervention: Proprioceptive training (PrT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 108
Study: 365391

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30506679

Group type: EXPERIMENTAL
Intervention: NCES suspended in PRP
Number of subjects: 21

Group type: COMPARATOR
Intervention: NCES suspended in PBS
Number of subjects: 21
Study: 27835048

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg OD + nifedipine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 108
Study: 25707379

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (designed to achieve and maintain >7% weight loss through increased physical activity and reduced caloric intake)
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Comparison group (received social support and diabetes education)
Number of subjects: 1019
Study: 24641486

Group type: EXPERIMENTAL
Intervention: Participants instructed to be consistent in the form of their gestures and to teach them to the experimenter.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants describing reversible events in pantomime.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants describing non-reversible events in pantomime.
Number of subjects: 0
Study: 22612061

Group type: EXPERIMENTAL
Intervention: Sulbactam‐ampicillin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Additional dose 12 hours after prophylaxis
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Prophylactic dose until nephrostomy tube removal
Number of subjects: 191
Study: 20020612

Group type: EXPERIMENTAL
Intervention: Imunofan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 17317221

Group type: EXPERIMENTAL
Intervention: Congruent stimulation of the rubber hand and the subject's hand with slight differences in posture.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent stimulation in hand‐centred space but congruent in external space.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mismatch between stimulation delivered to the subject's hand and the rubber hand.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small changes in the subject's hand posture.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posture transformations applied to the rubber hand.
Number of subjects: 0
Study: 15347709

Group type: EXPERIMENTAL
Intervention: VEGF gene therapy (naked plasmid DNA encoding for human VEGF165)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Laser therapy (direct myocardial revascularization)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard medical therapy (control)
Number of subjects: 35
Study: 11464069

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9504354

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg daily)
Number of subjects: 21
Study: 7519554

Group type: EXPERIMENTAL
Intervention: Bupivacaine-opioid mixture through a lumbar epidural catheter
Number of subjects: 19

Group type: COMPARATOR
Intervention: Continuous intravenous opioid
Number of subjects: 19
Study: 3354411

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral Lorcainide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous Lorcainide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 25
Study: 4335443

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (16,000 IU single oral dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (2,640 IU/day for 2 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (6,000 to 30,000 IU/day for 6 months to 2 years)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 25-hydroxycholecalciferol (2,640 IU/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 25-hydroxycholecalciferol (varied doses)
Number of subjects: 26
Study: 31116286

Group type: EXPERIMENTAL
Intervention: Elastomeric separators
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Kesling separators
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Kansal separators
Number of subjects: 108
Study: 27488859

Group type: EXPERIMENTAL
Intervention: Prasugrel for 6 weeks at loading/maintenance doses of 20/3.75 mg (Continued Group; n = 68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group; n = 68)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Prasugrel for 6 weeks (Continued Group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Switched Group (CYP2C19 gene polymorphisms)
Number of subjects: 136
Study: 25875843

Group type: EXPERIMENTAL
Intervention: 5 injections of HIV‐DNA, 1000 μg total dose (3 Env and 2 Gag encoding plasmids)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 2 injections of combined HIV‐DNA pools, 600 μg total dose
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 2 injections with separated pools of HIV‐DNA, 600 μg total dose
Number of subjects: 129
Study: 23557223

Group type: COMPARATOR
Intervention: C-Loop haptic design without CTR
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C-Loop haptic design with CTR
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Plate-haptic design
Number of subjects: 135
Study: 22036862

Group type: EXPERIMENTAL
Intervention: Hemoporfin 2.5 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemoporfin 5 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemoporfin 7.5 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemoporfin 10 mg/kg
Number of subjects: 36
Study: 20053235

Group type: EXPERIMENTAL
Intervention: ACASI-based feedback on reported HIV risk behaviors
Number of subjects: 566

Group type: COMPARATOR
Intervention: No intervention (no feedback)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: ACASI-based feedback
Number of subjects: 566
Study: 17176456

Group type: EXPERIMENTAL
Intervention: Metadoxine (MET)
Number of subjects: 160

Group type: COMPARATOR
Intervention: NULL (no drug treatment)
Number of subjects: 160
Study: 15630643

Group type: EXPERIMENTAL
Intervention: Incisional bupivacaine (0.5 ml/kg, 0.25% for <40 kg, 0.5% for >40 kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Incisional bupivacaine
Number of subjects: 68
Study: 10783565

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse (Corsodyl, CHX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available dentifrice supplementing fluoride (Odol‐med‐3)
Number of subjects: 12
Study: 8977510

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (1 puff)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1600983

Group type: EXPERIMENTAL
Intervention: 175 ms rate responsive AVD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 125 ms fixed AVD
Number of subjects: 10

Group type: COMPARATOR
Intervention: 250 ms fixed AVD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 125 ms AVD
Number of subjects: 10

Group type: COMPARATOR
Intervention: 250 ms AVD
Number of subjects: 10
Study: 3912182

Group type: EXPERIMENTAL
Intervention: 5 mg felodipine three times a day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg felodipine three times a day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (5 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (10 mg)
Number of subjects: 13
Study: 29502880

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to 33.5°C for 72 hours)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 303
Study: 24496044

Group type: EXPERIMENTAL
Intervention: Pregnenolone (50 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25115616

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg/d; n=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Matching placebo (control; n=27)
Number of subjects: 53